Golnar Rahimzadeh, Reza Valadan, Shaghayegh Rezai, Mohammad Khosravi, Laleh Vahedi Larijani, Somayeh Sheidaei, Ebrahim Nemati Hevelaee, Faezeh Sadat Movahedi, Raha Rezai, Mohammad Sadegh Rezai
{"title":"Evaluation of antibiotic resistance changes in <i>Acinetobacter baumannii</i> in the era of COVID-19 in Northern Iran.","authors":"Golnar Rahimzadeh, Reza Valadan, Shaghayegh Rezai, Mohammad Khosravi, Laleh Vahedi Larijani, Somayeh Sheidaei, Ebrahim Nemati Hevelaee, Faezeh Sadat Movahedi, Raha Rezai, Mohammad Sadegh Rezai","doi":"10.18502/ijm.v16i3.15762","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>During the coronavirus pandemic, the overuse of antibiotics to reduce coinfections and mortality may be contributing to the rise of antimicrobial resistance. In this study, we aim to investigate the antibiotic resistance changes of <i>Acinetobacter baumannii</i> post-COVID-19 pandemic in Northern Iran.</p><p><strong>Materials and methods: </strong>The current study is a cross-sectional study. Between 2022 and 2023, 2190 clinical samples were collected from patients with healthcare-associated infections (HAIs) at four hospitals in Sari, which served as corona centers after the COVID-19 pandemic. Antimicrobial sensitivity was determined using standard broth macro-dilution, and resistance genes were detected using multiplex PCR.</p><p><strong>Results: </strong>Based on the results co-amoxiclav had a resistance rate of 100%, while piperacillin/tazobactam showed the least resistance rate of 29.82%. In terms of GM MIC values, colistin was the most potent against multi-drug resistant isolates. The frequency of <i>bla</i> <sub>OXA-51</sub> , <i>ampC, aphA6,</i> and <i>bla</i> <sub>NDM</sub> genes were 100%, 99.12%, 90.35%, and 69.30% respectively.</p><p><strong>Conclusion: </strong>Our study revealed high multi-drug resistance rates. Piperacillin/tazobactam recommended for treating multi-drug resistant <i>Acinetobacter baumannii</i> infections in Northern Iran.</p>","PeriodicalId":14633,"journal":{"name":"Iranian Journal of Microbiology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245345/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijm.v16i3.15762","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: During the coronavirus pandemic, the overuse of antibiotics to reduce coinfections and mortality may be contributing to the rise of antimicrobial resistance. In this study, we aim to investigate the antibiotic resistance changes of Acinetobacter baumannii post-COVID-19 pandemic in Northern Iran.
Materials and methods: The current study is a cross-sectional study. Between 2022 and 2023, 2190 clinical samples were collected from patients with healthcare-associated infections (HAIs) at four hospitals in Sari, which served as corona centers after the COVID-19 pandemic. Antimicrobial sensitivity was determined using standard broth macro-dilution, and resistance genes were detected using multiplex PCR.
Results: Based on the results co-amoxiclav had a resistance rate of 100%, while piperacillin/tazobactam showed the least resistance rate of 29.82%. In terms of GM MIC values, colistin was the most potent against multi-drug resistant isolates. The frequency of blaOXA-51 , ampC, aphA6, and blaNDM genes were 100%, 99.12%, 90.35%, and 69.30% respectively.
Conclusion: Our study revealed high multi-drug resistance rates. Piperacillin/tazobactam recommended for treating multi-drug resistant Acinetobacter baumannii infections in Northern Iran.
期刊介绍:
The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.